PPD to support Merck & Co's vaccine development
This article was originally published in Scrip
Executive Summary
The CRO, PPD, is to support Merck & Co's vaccine portfolio with assay development and immunogenicity testing services over the next five years. PPD has bought Merck's 130,000sq ft vaccine testing laboratory and related equipment in Wayne, Pennsylvania, for an undisclosed sum and has hired almost 80 Merck professionals to run the facility. PPD plans to develop new technologies and assays to expand its immunochemistry and oncology vaccine testing services and biologics lab services for other clients. It will also provide traditional central laboratory and sample storage services to Merck for its clinical development activities for five years. The transaction closed at the end of last month.
You may also be interested in...
Innovation not M&A to drive Bayer growth in LatAm
Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.
2010 Scrip 100 - Is Anvisa a friend of innovators?
A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.
Elan raises $1.5 billion
Elan is raising $1.5 billion in bonds to refinance its existing debt and for general corporate purposes, it says.